- World Vaccine Congress: COVID-19 panel discussion, two oral
presentations highlighting Phase 3 Sci-B-Vac® data and VBI-1901
Phase 1/2a data - ID Week™: Two e-poster presentations featuring
Phase 3 Sci-B-Vac® data
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage
biopharmaceutical company developing next-generation infectious
disease and immuno-oncology vaccines, today announced upcoming
presentations highlighting data from multiple clinical programs –
including Sci-B-Vac®, the company’s 3-antigen hepatitis B vaccine;
VBI-2900, the company’s coronavirus vaccine program; and VBI-1901,
the company’s cancer vaccine immunotherapeutic – at the World
Vaccine Congress Washington 2020 and ID Week 2020™.
Presentation Details
World Vaccine Congress Washington 2020: September 28 –
October 1, 2020
COVID-19 Panel Discussion: What existing treatments and
vaccine development platforms show promise to control the rate of
infection and spread? Session: Emerging and Infectious
Participant: David E. Anderson, Ph.D., VBI’s Chief
Scientific Officer Date: Monday, September 28, 2020
Time: 3:50 – 5:20 PM ET
Presentation: Sci-B-Vac: Results on Ph3 Hep B vaccine
Session: Emerging and Infectious Presenter: Francisco
Diaz-Mitoma, M.D., VBI’s Chief Medical Officer Date:
Tuesday, September 29, 2020 Time: 4:35 – 5:05 PM ET
Presentation: Targeting CMV for the development of
effective GBM immunotherapy Session: Cancer &
Immunotherapy Presenter: David E. Anderson, Ph.D., VBI’s
Chief Scientific Officer Date: Wednesday, September 30, 2020
Time: 1:40 – 2:10 PM ET
World Vaccine Congress Event Website:
https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
ID Week 2020™: October 21-25, 2020
Poster #: 8 Title: Higher hepatitis B antibody
titers induced in all adults vaccinated with a tri-antigenic
hepatitis B (HBV) vaccine, compared to a mono-antigenic HBV
vaccine: results from two pivotal phase 3 double-blind, randomized
studies (PROTECT and CONSTANT) Poster Session: Adult
Vaccines Presenter: Joanne Langley, M.D., Professor of
Pediatrics and Community Health and Epidemiology, CIHR-GSK Chair in
Pediatric Vaccinology, Dalhousie University, and Head of the
Division of Infectious Disease, IWK Health Centre, and principal
investigator of the PROTECT study Date: Available October
21-25, 2020
Poster #: 1051 Title: Rapid onset of
seroprotection rates in young adults immunized with a tri-antigenic
hepatitis B virus (HBV) vaccine compared to a mono-antigenic HBV
vaccine Poster Session: Hepatitis Presenter: Timo
Vesikari M.D., Ph.D., Professor Emeritus and Director of the Nordic
Vaccine Research Network in Finland, and principal investigator of
the PROTECT and CONSTANT Phase 3 clinical studies Date:
Available October 21-25, 2020
ID Week 2020™ Event Website:
https://www.eventscribe.com/2020/IDWeek/
About Sci-B-Vac®
Sci-B-Vac® is a licensed, third-generation hepatitis B vaccine
that has demonstrated safety and efficacy in over 750,000 patients.
Sci-B-Vac® is the only 3-antigen hepatitis B vaccine, comprised of
the S, pre-S1, and pre-S2 surface antigens of the hepatitis B
virus, and is approved for use and commercially-available in
Israel. In December 2017, VBI initiated patient dosing in a global
Phase 3 clinical program that consisted of two concurrent pivotal
studies: PROTECT, a safety and immunogenicity study, and CONSTANT,
a lot-to-lot consistency study. Data from both the PROTECT study
and the CONSTANT study, which were announced in June 2019 and
January 2020, respectively, will comprise the basis for the
regulatory submissions in the U.S., Europe, and Canada, expected to
begin in the fourth quarter 2020.
To learn more about Sci-B-Vac®, visit:
https://www.vbivaccines.com/sci-b-vac/
About VBI-1901 and GBM
VBI-1901 is a novel cancer vaccine immunotherapeutic candidate
developed using VBI’s enveloped virus-like particle (eVLP)
technology to target two highly immunogenic cytomegalovirus (CMV)
antigens, gB and pp65. Scientific literature suggests CMV infection
is prevalent in multiple solid tumors, including glioblastoma
(GBM). GBM is among the most common and aggressive malignant
primary brain tumors in humans. In the U.S. alone, 12,000 new cases
are diagnosed each year. The current standard of care for treating
GBM is surgical resection, followed by radiation and chemotherapy.
Even with aggressive treatment, GBM progresses rapidly and is
exceptionally lethal.
About Coronaviruses
Coronaviruses are a large family of enveloped viruses that
usually cause respiratory illness of varying severities, including
the common cold and pneumonia. Only seven coronaviruses are known
to cause disease in humans, four of which most frequently cause
symptoms of the common cold. Three of the seven coronaviruses,
however, have more serious outcomes in people: (1) SARS-CoV-2, a
novel coronavirus identified as the cause of coronavirus disease
2019 (COVID-19); (2) MERS-CoV, identified in 2012 as the cause of
Middle East respiratory syndrome (MERS); and (3) SARS-CoV,
identified in 2002 as the cause of an outbreak of severe acute
respiratory syndrome (SARS).1,2
About VBI Vaccines Inc.
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage
biopharmaceutical company developing a next generation of vaccines
to address unmet needs in infectious disease and immuno-oncology.
VBI is advancing the prevention and treatment of hepatitis B, with:
(1) the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is
approved for use and commercially available in Israel and recently
completed its Phase 3 program in the U.S., Europe, and Canada; and
(2) an immunotherapeutic in development for a functional cure for
chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP)
platform technology enables development of eVLPs that closely mimic
the target virus to elicit a potent immune response. VBI’s lead
eVLP programs include a vaccine immunotherapeutic candidate
targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV)
vaccine candidate, and a prophylactic pan-coronavirus vaccine
candidate. VBI is headquartered in Cambridge, MA, with research
operations in Ottawa, Canada, and research and manufacturing
facilities in Rehovot, Israel. Website Home:
http://www.vbivaccines.com/ News and Insights:
http://www.vbivaccines.com/wire/ Investors:
http://www.vbivaccines.com/investors/
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are
forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
and are forward-looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”). The
Company cautions that such statements involve risks and
uncertainties that may materially affect the Company’s results of
operations. Such forward-looking statements are based on the
beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including but not
limited to, the impact of general economic, industry or political
conditions in the United States or internationally; the impact of
the ongoing COVID-19 pandemic on our clinical studies,
manufacturing, business plan, and the global economy; the ability
to establish that potential products are efficacious or safe in
preclinical or clinical trials; the ability to establish or
maintain collaborations on the development of therapeutic
candidates; the ability to obtain appropriate or necessary
governmental approvals to market potential products; the ability to
obtain future funding for developmental products and working
capital and to obtain such funding on commercially reasonable
terms; the Company’s ability to manufacture product candidates on a
commercial scale or in collaborations with third parties; changes
in the size and nature of competitors; the ability to retain key
executives and scientists; and the ability to secure and enforce
legal rights related to the Company’s products. A discussion of
these and other factors, including risks and uncertainties with
respect to the Company, is set forth in the Company’s filings with
the SEC and the Canadian securities authorities, including its
Annual Report on Form 10-K filed with the SEC on March 5, 2020, and
filed with the Canadian security authorities at sedar.com on March
5, 2020, as may be supplemented or amended by the Company’s
Quarterly Reports on Form 10-Q. Given these risks, uncertainties
and factors, you are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety
by this cautionary statement. All such forward-looking statements
made herein are based on our current expectations and we undertake
no duty or obligation to update or revise any forward-looking
statements for any reason, except as required by law.
1 “Coronavirus.” World Health Organization,
https://www.who.int/health-topics/coronavirus. 2 “Coronaviruses.”
National Institute of Allergy and Infectious Diseases,
https://www.niaid.nih.gov/diseases-conditions/coronaviruses
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200924005252/en/
VBI Nicole Anderson Director, Corporate Communications
& IR Phone: (617) 830-3031 x124 Email: IR@vbivaccines.com
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2024 to May 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to May 2024